Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0044-1788557
Review Article

Management of Unresectable Cholangiocarcinoma Using Modern Radiation Therapy Techniques

Deniz Demircioglu
1   Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Lou-Anne Acevedo Moreno
1   Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
,
William A. Hall 
1   Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Cholangiocarcinoma (CCA) is a malignancy of epithelial cells in the bile duct, categorized based on its anatomical location as intrahepatic, perihilar, or extrahepatic. It has a low prevalence of ∼1.6 cases per 100,000 people in the United States, but has a poor prognosis. All stages included, CCA has a 5-year survival rate of less than 10%. The preferred curative treatment for intrahepatic, perihilar, and extrahepatic CCA is surgical resection combined with systemic chemotherapy. However, resection is not always a viable option for many patients, as the disease is often discovered at the time of diagnosis to be either metastatic or locally advanced precluding surgical resection. In this setting, a variety of options can be used, one of which is radiation therapy (RT). The administration of RT has evolved tremendously over the past decades. Total doses given can be limited by a tumor's proximity to regional normal organs such as the liver, stomach, bile duct, and small and large bowel. When a CCA is unresectable, it is often in close proximity to radiosensitive organs. Delivering RT in this setting therefore requires precise delivery techniques. An emerging technique known broadly as stereotactic body radiation therapy (SBRT) or stereotactic ablative body radiation therapy gives a highly focused, often ablative, form of RT to a defined and specific target. Categorically, SBRT offers a quick and efficient management option, in some cases only one to three total treatments. This narrative reviews various applications of SBRT for cholangiocarcinoma including SBRT alone, SBRT with chemotherapy, SBRT with chemotherapy followed by a liver transplantation (orthotopic liver transplantation), and finally novel combinations of SBRT with immunotherapy.

Keywords

stereotactic body radiation therapy - cholangiocarcinoma - SABR therapy


Publication History

Received: 28 April 2024

Accepted: 24 June 2024

Article published online:
17 July 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Brindley PJ, Bachini M, Ilyas SI. et al. Cholangiocarcinoma. Nat Rev Dis Primers 2021; 7 (01) 65
    CrossrefPubMedGoogle Scholar
  • 2 Banales JM, Cardinale V, Carpino G. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13 (05) 261-280
    CrossrefPubMedGoogle Scholar
  • 3 Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145 (06) 1215-1229
    CrossrefPubMedGoogle Scholar
  • 4 de Jong MC, Nathan H, Sotiropoulos GC. et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29 (23) 3140-3145
    CrossrefPubMedGoogle Scholar
  • 5 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020; 72 (01) 95-103
    CrossrefPubMedGoogle Scholar
  • 6 Cillo U, Fondevila C, Donadon M. et al. Surgery for cholangiocarcinoma. Liver Int 2019; 39 (Suppl, Suppl 1): 143-155
    CrossrefPubMedGoogle Scholar
  • 7 Hoehn RS, Wima K, Ertel AE. et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol 2015; 22 (Suppl. 03) S1133-S1139
    CrossrefPubMedGoogle Scholar
  • 8 Ecker BL, Vining CC, Roses RE. et al. Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis. Ann Surg Oncol 2017; 24 (13) 3926-3933
    CrossrefPubMedGoogle Scholar
  • 9 Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R. Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. HPB (Oxford) 2016; 18 (10) 843-850
    CrossrefPubMedGoogle Scholar
  • 10 Kim YS, Oh SY, Go SI. et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Cancer Chemother Pharmacol 2017; 79 (01) 99-106
    CrossrefPubMedGoogle Scholar
  • 11 Kim YS, Hwang IG, Park SE. et al. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemother Pharmacol 2016; 77 (05) 979-985
    CrossrefPubMedGoogle Scholar
  • 12 Kopek N, Holt MI, Hansen AT, Høyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94 (01) 47-52
    CrossrefPubMedGoogle Scholar
  • 13 Duignan S, Maguire D, Ravichand CS. et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford) 2014; 16 (01) 91-98
    CrossrefPubMedGoogle Scholar
  • 14 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47
    CrossrefPubMedGoogle Scholar
  • 15 Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 2006; 16 (02) 77-84
    CrossrefPubMedGoogle Scholar
  • 16 Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019; 195 (02) 93-102
    CrossrefPubMedGoogle Scholar
  • 17 Potters L, Kavanagh B, Galvin JM. et al; American Society for Therapeutic Radiology and Oncology, American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76 (02) 326-332
    CrossrefPubMedGoogle Scholar
  • 18 Haridass A. Developments in stereotactic body radiotherapy. Cancers (Basel) 2018; 10 (12) 497
    CrossrefPubMedGoogle Scholar
  • 19 Tao R, Krishnan S, Bhosale PR. et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016; 34 (03) 219-226
    CrossrefPubMedGoogle Scholar
  • 20 Mahadevan A, Dagoglu N, Mancias J. et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015; 6 (11) 1099-1104
    CrossrefPubMedGoogle Scholar
  • 21 Cheng Y, Lin Y, Long Y. et al. Is the CyberKnife© radiosurgery system effective and safe for patients? An umbrella review of the evidence. Future Oncol 2022; 18 (14) 1777-1791
    CrossrefPubMedGoogle Scholar
  • 22 Zhang XX, Ma HB, Li TH, Huang B, Jia NY, Meng Y. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma. Clin Transl Oncol 2023; 25 (03) 731-738
    CrossrefPubMedGoogle Scholar
  • 23 Weiner AA, Olsen J, Ma D. et al. Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II institutional study. Radiother Oncol 2016; 121 (01) 79-85
    CrossrefPubMedGoogle Scholar
  • 24 Gkika E, Hallauer L, Kirste S. et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer 2017; 17 (01) 781
    CrossrefPubMedGoogle Scholar
  • 25 Sandler KA, Veruttipong D, Agopian VG. et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol 2016; 1 (04) 237-243
    CrossrefPubMedGoogle Scholar
  • 26 Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67
    CrossrefPubMedGoogle Scholar
  • 27 Jung DH, Kim MS, Cho CK. et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 2014; 32 (03) 163-169
    CrossrefPubMedGoogle Scholar
  • 28 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget 2017; 8 (55) 93541-93550
    CrossrefPubMedGoogle Scholar
  • 29 Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol 2019; 19: 66-71
    CrossrefPubMedGoogle Scholar
  • 30 Torgeson A, Lloyd S, Boothe D. et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis. Ann Surg Oncol 2017; 24 (13) 4001-4008
    CrossrefPubMedGoogle Scholar
  • 31 Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol 2017; 193 (08) 620-629
    CrossrefPubMedGoogle Scholar
  • 32 Welling TH, Feng M, Wan S. et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl 2014; 20 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 33 Wu TC, Deng J, Chu FI. et al. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma. HPB (Oxford) 2024; 26 (03) 444-450
    CrossrefPubMedGoogle Scholar
  • 34 Ziogas IA, Giannis D, Economopoulos KP. et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates. Transplantation 2021; 105 (10) 2263-2271
    CrossrefPubMedGoogle Scholar
  • 35 Hong JC, Jones CM, Duffy JP. et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146 (06) 683-689
    CrossrefPubMedGoogle Scholar
  • 36 Wong M, Kim J, George B. et al. Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: a prospective pilot study. J Surg Res 2019; 242: 23-30
    CrossrefPubMedGoogle Scholar
  • 37 Wu TC, Smith CP, Li JS. et al. A systematic review and meta-analysis of pathologic complete response rates for patients with cholangiocarcinoma treated on liver transplant protocols. J Surg Oncol 2024; 129 (03) 574-583
    CrossrefPubMedGoogle Scholar
  • 38 Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 2019; 7 (01) 204
    CrossrefPubMedGoogle Scholar
  • 39 Zhao Q, Chen Y, Du S. et al. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021; 22 (03) 175-183
    CrossrefPubMedGoogle Scholar
  • 40 Kreidieh M, Zeidan YH, Shamseddine A. The combination of stereotactic body radiation therapy and immunotherapy in primary liver tumors. J Oncol 2019; 2019: 4304817
    CrossrefPubMedGoogle Scholar
  • 41 Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma. Cancers (Basel) 2022; 15 (01) 50
    CrossrefPubMedGoogle Scholar
  • 42 Kelley RK, Ueno M, Yoo C. et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853-1865
    CrossrefPubMedGoogle Scholar
  • 43 Zhu C, Li H, Yang X. et al. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study. Cancer Immunol Immunother 2023; 72 (09) 2949-2960
    CrossrefPubMedGoogle Scholar
  • 44 Elias C, Zeidan YH, Bouferraa Y. et al. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer 2022; 22 (01) 1296
    CrossrefPubMedGoogle Scholar